The decline of the Helsinki stock exchange corrected itself during the evening and the OMXH general index finally ended with a rise of 0.01 percent to 9,495.81 points on Wednesday.
Mining and prospecting company Endomines Finland updated its production guidelines for the current year on Wednesday. The company now expects the production volume to increase by 8–15 percent compared to the 2023 production volume. The company said in its guidelines at the beginning of the year that production will increase by 15–35 percent.
“The slowdown in production volume growth is due to the production challenges we faced at the end of the year, which have temporarily slowed down our operations. Our production will continue to grow clearly from 2023 and the high price of gold supports our operations. We see the challenges faced as an unfortunate bump on our way towards future production levels”, CEO Kari Vyhtinen says.
Endomines shares fell by 7.3 percent to 7.36 euros.
compound calculates its guidance for turnover and EBITDA for the year 2024.
The possible development of customers’ sales volumes, poor availability of raw materials, rising costs of raw materials and electrical energy, and the general economic, labor market, and competitive situation may affect the business outlook.
In addition, due to the tightened geopolitical situation, there are uncertainties in the future development of sales and profitability.
Componenta expects the group’s turnover in 2024 to remain the same as the previous year. EBITDA accumulated from operational business is also expected to remain the same as the previous year. In the previous guidance, it expected the group’s turnover and EBITDA to improve from the previous year.
“Despite our previous prospects and short-term expectations, demand and, with it, our open order backlog have decreased for the rest of the year. managing director Sami Sivuranta says in the announcement.
The reason for this is mainly the low level of demand prevailing due to the general economic situation and the detailed production plans of the customers’ own factories for the turn of the year, as a result of which deliveries have been moved to 2025.
“In the end of the year, the situation will also be weakened by the negotiation situation of collective agreements and labor market disturbances, especially with the strike threat and strike announcements.”
Componenta fell by 9.7 percent to 2.43 euros.
Drug developer Pharaoh reported phase 2 results from an ongoing trial of BEXMAB in patients with myelodysplastic syndrome (MDS) unresponsive to hypomethylating agents (HMA), also known as relapsed/resistant MDS.
Preliminary phase 2 results of the BEXMAB trial have already shown a high objective response rate of 79 percent (11/14) in MDS patients treated with the combination of bexmarilimab and azacitidine who did not respond to HMA.
Now a total of 20 corresponding patients can be evaluated with this new combination. The treatment has been well tolerated, without dose-limiting toxicity. The objective response is 80 percent (16/20).
The BEXMAB study continues to recruit patients as planned, with the next study data readout expected in late Q1 2025.
The share rose 10.9 percent to 2.14 euros.
Premises implementer Tekova plans to list on the stock exchange’s First North list.
The planned IPO would be carried out in December as a technical IPO, i.e. no share issue or sale will be organized in connection with it. Acting CEO Jaakko Heikkilän at this stage, the motive for the listing is to improve the company’s recognition and credibility.
The company specializes in the construction of business, office, logistics, production and sports facilities. In total, the company has implemented about a hundred projects.
Nightingale Health announced that it will investigate the transfer of its B-series shares to the main list of the Helsinki Stock Exchange and the start of trading on the OTCQX market in the United States.
The share rose 15 percent to 3.14 euros.
Source: www.arvopaperi.fi
